LT3226905T - Hyaluronan conjugates with pharmaceutically active substances, methods and compositions - Google Patents

Hyaluronan conjugates with pharmaceutically active substances, methods and compositions

Info

Publication number
LT3226905T
LT3226905T LTEPPCT/IB2015/051331T LT15051331T LT3226905T LT 3226905 T LT3226905 T LT 3226905T LT 15051331 T LT15051331 T LT 15051331T LT 3226905 T LT3226905 T LT 3226905T
Authority
LT
Lithuania
Prior art keywords
compositions
methods
active substances
pharmaceutically active
hyaluronan conjugates
Prior art date
Application number
LTEPPCT/IB2015/051331T
Other languages
Lithuanian (lt)
Inventor
Bengt Lindqvist
Rune Ringom
Original Assignee
Synartro Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synartro Ab filed Critical Synartro Ab
Publication of LT3226905T publication Critical patent/LT3226905T/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
LTEPPCT/IB2015/051331T 2014-02-27 2015-02-21 Hyaluronan conjugates with pharmaceutically active substances, methods and compositions LT3226905T (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461945491P 2014-02-27 2014-02-27
PCT/IB2015/051331 WO2015128787A1 (en) 2014-02-27 2015-02-21 Hyaluronan conjugates with pharmaceutically active substances, methods and compositions

Publications (1)

Publication Number Publication Date
LT3226905T true LT3226905T (en) 2022-03-10

Family

ID=52693002

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IB2015/051331T LT3226905T (en) 2014-02-27 2015-02-21 Hyaluronan conjugates with pharmaceutically active substances, methods and compositions

Country Status (14)

Country Link
US (3) US10660906B2 (en)
EP (2) EP3988121A1 (en)
CA (1) CA2974611C (en)
CY (1) CY1125005T1 (en)
DK (1) DK3226905T3 (en)
ES (1) ES2905606T3 (en)
HR (1) HRP20220176T1 (en)
HU (1) HUE057871T2 (en)
LT (1) LT3226905T (en)
PL (1) PL3226905T3 (en)
PT (1) PT3226905T (en)
RS (1) RS62909B1 (en)
SI (1) SI3226905T1 (en)
WO (1) WO2015128787A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220176T1 (en) * 2014-02-27 2022-04-29 Synartro Ab Hyaluronan conjugates with pharmaceutically active substances, methods and compositions
CN110430884A (en) * 2017-03-14 2019-11-08 生化学工业株式会社 Joint disease disposition composition and kit containing it
WO2020101013A1 (en) 2018-11-16 2020-05-22 生化学工業株式会社 Pharmaceutical composition
CN113750255B (en) * 2021-09-30 2023-10-31 大连民族大学 Environment-responsive hyaluronic acid-podophyllotoxin prodrug micelle and preparation method and application thereof
WO2024038087A1 (en) 2022-08-16 2024-02-22 Synartro Ab Method for preparing sterile compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE442820B (en) 1984-06-08 1986-02-03 Pharmacia Ab GEL OF THE CROSS-BOND HYALURONIC ACID FOR USE AS A GLASS BODY SUBSTITUTE
IT1281877B1 (en) 1995-05-10 1998-03-03 Fidia Advanced Biopolymers Srl Heavy metal salts of succinyl derivatives of hyaluronic acid and their use as potential therapeutic agents
IT1281876B1 (en) 1995-05-10 1998-03-03 Fidia Advanced Biopolymers Srl HYALURONIC ACID AND ITS ESTER DERIVATIVES FOR THE PREPARATION OF MATRIXES FOR THE CONTROLLED RELEASE OF DRUGS.
IT1294797B1 (en) * 1997-07-28 1999-04-15 Fidia Advanced Biopolymers Srl USE OF HYALURONIC ACID DERIVATIVES IN THE PREPARATION OF BIOMATERIALS WITH PHYSICAL AND BUFFERING HEMOSTATIC ACTIVITIES
DE19882079D2 (en) 1997-12-31 2000-11-16 Schleifring Und App Bau Gmbh Arrangement for the transmission of electrical signals and / or energy
ATE276257T1 (en) * 2000-06-30 2004-10-15 Banyu Pharma Co Ltd PYRAZINONE DERIVATIVES
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
JP2004099581A (en) * 2002-09-09 2004-04-02 Masashi Takahashi Anti-inflammatory agent
EP1710257A4 (en) 2004-01-07 2011-03-23 Seikagaku Kogyo Co Ltd Hyaluronic acid derivative and drug containing the same
JP5043364B2 (en) * 2006-05-01 2012-10-10 生化学工業株式会社 Method for producing polysaccharide derivative
IE20070900A1 (en) 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
EP2485767A1 (en) * 2009-10-06 2012-08-15 Ascendis Pharma A/S Carrier linked paliperidone prodrugs
US20150010634A1 (en) * 2011-10-12 2015-01-08 Ascendis Pharma Ophthamology Division A/S Prevention and treatment of ocular conditions
GB2510587B (en) * 2013-02-07 2020-05-20 Orthopaedic Res Uk Biospecific agents for bone
HRP20220176T1 (en) 2014-02-27 2022-04-29 Synartro Ab Hyaluronan conjugates with pharmaceutically active substances, methods and compositions

Also Published As

Publication number Publication date
PT3226905T (en) 2022-01-19
RS62909B1 (en) 2022-03-31
SI3226905T1 (en) 2022-04-29
WO2015128787A1 (en) 2015-09-03
DK3226905T3 (en) 2022-01-24
US10660906B2 (en) 2020-05-26
EP3988121A1 (en) 2022-04-27
CY1125005T1 (en) 2023-01-05
EP3226905B1 (en) 2021-12-22
US11229656B2 (en) 2022-01-25
US20160367684A1 (en) 2016-12-22
US20220168320A1 (en) 2022-06-02
PL3226905T3 (en) 2022-04-19
EP3226905A1 (en) 2017-10-11
US20200237783A1 (en) 2020-07-30
HRP20220176T1 (en) 2022-04-29
CA2974611A1 (en) 2015-09-03
US11642357B2 (en) 2023-05-09
HUE057871T2 (en) 2022-06-28
ES2905606T3 (en) 2022-04-11
CA2974611C (en) 2022-07-12

Similar Documents

Publication Publication Date Title
IL290116A (en) Hydrophilic antibody-drug conjugates
IL258248A (en) Affinity-oligonucleotide conjugates and uses thereof
HK1231367A1 (en) Antibody-drug conjugates, their preparation and their therapeutic use
IL248221B (en) Antibody-drug conjugates with high drug loading
IL248239A0 (en) Anti - her3 antibody - drug conjugates, compositions comprising same and uses thereof
EP3137114B8 (en) Anti-ptk7 antibody-drug conjugates
EP3142705A4 (en) Polymer-flavonoid conjugate and uses thereof
PT3223796T (en) Pharmaceutical compositions, preparation and uses thereof
IL252397A0 (en) Pharmaceutical composition, preparation and uses thereof
IL290114A (en) Pharmaceutical composition, preparation and uses thereof
ZA201703398B (en) Pharmaceutical composition and methods
ZA201608327B (en) Curcumin-peptide conjugates and formulations thereof
EP3207149A4 (en) Pharmaceutical composition with improved stability
AU2016349786B2 (en) Anti-CD3-folate conjugates and their uses
PL3226905T3 (en) Hyaluronan conjugates with pharmaceutically active substances, methods and compositions
LT3229843T (en) Pharmaceutical composition, preparation and uses thereof
EP3143036A4 (en) Par-1 based therapeutic conjugates and uses thereof